PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein expressed only on the surface of myeloma cells. This initiates antibody-dependent cytotoxic activity which targets myeloma cells while leaving healthy cells intact.
Jeremy Moon, CEO Icebreaker
The XVIVO groups combination of scientific and design expertise means their work is unmatched and of a high standard. We were very pleased with the final product and it has been well received by audiences across the globe. We would absolutely recommend working with XVIVO.